Analysts think AVTX stock price could increase by 305%
Dec 26, 2024, 12:25 PM
-14.42%
What does AVTX do
Avalo Therapeutics, a clinical-stage biotechnology company headquartered in Rockville, Maryland, focuses on immune dysregulation therapies, with key assets including AVTX-009, quisovalimab, and AVTX-008. The company went public on November 13, 2015, and employs 19 people.
5 analysts think AVTX stock price will increase by 305.22%. The current median analyst target is $35.70 compared to a current stock price of $8.81. The lowest analysts target is $24.24 and the highest analyst target is $42.00.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
